This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.
Retatrutide (LY-343794)
Investigational triple agonist (GIP/GLP-1/glucagon receptors) studied for obesity; not a dietary supplement. Phase 2 data are robust; phase 3 TRIUMPH program is ongoing.
Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.
Retatrutide produced substantial mean body-weight reductions over 48 weeks (up to ~24% at highest dose), with larger losses at higher doses; GI adverse effects were common & dose-related.
The TRIUMPH phase 3 program (4 trials, >5800 participants) evaluates once-weekly subcutaneous retatrutide vs. placebo for weight management & obesity-related complications (OSA, OA, CVD). No primary efficacy results published as of early 2026; design & rationale published in 2025.
Stacks containing Retatrutide (LY-343794)
Public community stacks that include this ingredient.
Clinical Weight Loss Protocol
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).
Your personalized stack
Built from your goals & the supplement evidence library. You can edit doses & timing.
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).